Doç. Dr. Suade Özlem BADAK | AVESİS

Akademik Veri Yönetim Sistemi

Desteklenen Projeler

Desteklenen Projeler 1

2020 - Devam Ediyor A randomized, double-blind, placebo-conrolled, parallel group, phase III multicenter study of intravenous secukinumab to compare efficacy at 16 weeks with placebo and to assess safety and tolerability up to 52 weeks in subjects with active Ankylosing Spondylitis or non-radiographic axial SpondyloArthritis

Diğer Uluslararası Fon Programları

BADAK S. Ö.